ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1893

“From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)
Abstract Number: 1123

“It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life
Abstract Number: PP11

“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Abstract Number: 1165

“What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
Abstract Number: 1904

“Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis
Abstract Number: 1610

“You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians
Abstract Number: 1864

18F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis
Abstract Number: 0503

18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Abstract Number: 0287

20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compared to Diabetes
Abstract Number: 0282

5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management: A Population-based Cohort Study
Abstract Number: 1273

A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and Associated Interferon Gene Signature
Abstract Number: 1390

A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis
Abstract Number: 0674

A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Abstract Number: 1707

A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis
Abstract Number: 1203

A Change in a Patient Informed Clinical Disease Activity Index (PTCDAI) Is Similar to Their Rheumatologists CDAI When Following Patients with Early RA in the Canadian Early Arthritis Cohort (CATCH) Study

1
2
3
…
132
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].